Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature

Molecular Therapy

Volumn 22, Issue 1, 2014, Pages 59-68

  Condiotti, Reba ^a   Goldenberg, Daniel ^a   Giladi, Hilla ^a   Schnitzer Perlman, Temima ^a   Waddington, Simon N ^b,c   Buckley, Suzanne MK ^d   Heim, Denise ^e   Cheung, Wing ^b   Themis, Matthew ^f   Coutelle, Charles ^g   Simerzin, Alina ^a   Osejindu, Emma ^f   Wege, Henning ^e   Themis, Michael ^f,h   Galun, Eithan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f BRUNEL UNIVERSITY   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FELINE LENTIVIRUS VECTOR; LENTIVIRUS VECTOR; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; E2F GENE; FETUS; GENE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; MUTAGENESIS; NONHUMAN; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS DNA CELL DNA INTERACTION;

FELIDAE; MUS;

ANIMALS; CATS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DNA DAMAGE; E2F TRANSCRIPTION FACTORS; FETUS; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; LENTIVIRUSES, FELINE; LIVER NEOPLASMS; MICE; MUTAGENESIS, INSERTIONAL; TRANSCRIPTOME; TRANSDUCTION, GENETIC; TRANSGENES; VIRUS INTEGRATION;

EID: 84891836253     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.193     Document Type: Article

References (50)

1. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975
2. Kohn, DB (2010). Update on gene therapy for immunodeficiencies. Clin Immunol 135: 247-254
3. Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204
4. Buchholz, CJ and Cichutek, K (2006). Is it going to be SIN?: A European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: Initiative on hold. J Gene Med 8: 1274-1276
5. Xu, W, Russ, JL and Eiden, MV (2012). Evaluation of residual promoter activity in ?-retroviral self-inactivating (SIN) vectors. Mol Ther 20: 84-90
6. Modlich, U, Schambach, A, Brugman, MH, Wicke, DC, Knoess, S, Li, Z et al. (2008). Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 22: 1519-1528
7. Biffi, A, Montini, E, Lorioli, L, Cesani, M, Fumagalli, F, Plati, T et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341: 1233158
8. Aiuti, A, Biasco, L, Scaramuzza, S, Ferrua, F, Cicalese, MP, Baricordi, C et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341: 1233151
9. Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature 467: 318-322
10. Ranzani, M, Cesana, D, Bartholomae, CC, Sanvito, F, Pala, M, Benedicenti, F et al. (2013). Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 10: 155-161
11. Montini, E and Cesana, D (2012). Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a-/- mice. Meth Enzymol 507: 171-185
12. Ginn, SL, Liao, SH, Dane, AP, Hu, M, Hyman, J, Finnie, JW et al. (2010). Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther 18: 965-976
13. Themis, M, Waddington, SN, Schmidt, M, von Kalle, C, Wang, Y, Al-Allaf, F et al. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 12: 763-771
14. Nowrouzi, A, Cheung, WT, Li, T, Zhang, X, Arens, A, Paruzynski, A et al. (2013). The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis. Mol Ther 21: 324-337
15. Poeschla, EM and Looney, DJ (1998). CXCR4 is required by a nonprimate lentivirus: Heterologous expression of feline immunodeficiency virus in human, rodent, and feline cells. J Virol 72: 6858-6866
16. Hallstrom, TC and Nevins, JR (2009). Balancing the decision of cell proliferation and cell fate. Cell Cycle 8: 532-535
17. Polager, S and Ginsberg, D (2009). p53 and E2f: Partners in life and death. Nat Rev Cancer 9: 738-748
18. Pickering, MT and Kowalik, TF (2006). Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 25: 746-755
19. Chen, HZ, Tsai, SY and Leone, G (2009). Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev Cancer 9: 785-797
20. Conner, EA, Lemmer, ER, Omori, M, Wirth, PJ, Factor, VM and Thorgeirsson, SS (2000). Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 19: 5054-5062
21. Waddington, SN, Mitrophanous, KA, Ellard, FM, Buckley, SM, Nivsarkar, M, Lawrence, L et al. (2003). Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. Gene Ther 10: 1234-1240
22. Condiotti, R, Curran, MA, Nolan, GP, Giladi, H, Ketzinel-Gilad, M, Gross, E et al. (2004). Prolonged liver-specific transgene expression by a non-primate lentiviral vector. Biochem Biophys Res Commun 320: 998-1006
23. Grinshpun, A, Condiotti, R, Waddington, SN, Peer, M, Zeig, E, Peretz, S et al. (2010). Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector. Mol Ther 18: 1592-1598
24. Yang, F, Zhang, L, Huo, XS, Yuan, JH, Xu, D, Yuan, SX et al. (2011). Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 54: 1679-1689
25. Bester, AC, Schwartz, M, Schmidt, M, Garrigue, A, Hacein-Bey-Abina, S, Cavazzana- Calvo, M et al. (2006). Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther 13: 1057-1059
26. Letouzé, E, Allory, Y, Bollet, MA, Radvanyi, F and Guyon, F (2010). Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. Genome Biol 11: R76
27. Cesana, D, Sgualdino, J, Rudilosso, L, Merella, S, Naldini, L and Montini, E (2012). Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 122: 1667-1676
28. Moiani, A, Paleari, Y, Sartori, D, Mezzadra, R, Miccio, A, Cattoglio, C et al. (2012). Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 122: 1653-1666
29. Schröder, AR, Shinn, P, Chen, H, Berry, C, Ecker, JR and Bushman, F (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529
30. Halazonetis, TD, Gorgoulis, VG and Bartek, J (2008). An oncogene-induced DNA damage model for cancer development. Science 319: 1352-1355
31. Carter, SL, Eklund, AC, Kohane, IS, Harris, LN and Szallasi, Z (2006). A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048
32. Mayhew, CN, Carter, SL, Fox, SR, Sexton, CR, Reed, CA, Srinivasan, SV et al. (2007). RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology 133: 976-984
33. Biswas, AK and Johnson, DG (2012). Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res 72: 13-17
34. Marion, MJ, Hantz, O and Durantel, D (2010). The HepaRG cell line: Biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol 640: 261-272
35. Pelascini, LP, Janssen, JM and Gonçalves, MA (2013). Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells. Hum Gene Ther 24: 78-96
36. Stevenson, LF, Sparks, A, Allende-Vega, N, Xirodimas, DP, Lane, DP and Saville, MK (2007). The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 26: 976-986
37. Leu, JI and George, DL (2007). Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev 21: 3095-3109
38. Katzenellenbogen, M, Mizrahi, L, Pappo, O, Klopstock, N, Olam, D, Jacob-Hirsch, J et al. (2007). Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol Cancer Res 5: 1159-1170
39. Hallstrom, TC, Mori, S and Nevins, JR (2008). An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13: 11-22
40. Modlich, U and Baum, C (2009). Preventing and exploiting the oncogenic potential of integrating gene vectors. J Clin Invest 119: 755-758
41. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419
42. Calmels, B, Ferguson, C, Laukkanen, MO, Adler, R, Faulhaber, M, Kim, HJ et al. (2005). Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106: 2530-2533
43. Lin, WC, Lin, FT and Nevins, JR (2001). Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15: 1833-1844
44. Cooper, A, García, M, Petrovas, C, Yamamoto, T, Koup, RA and Nabel, GJ (2013). HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 498: 376-379
45. Boyault, S, Rickman, DS, de Reyniès, A, Balabaud, C, Rebouissou, S, Jeannot, E et al. (2007). Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45: 42-52
46. Vesselinovitch, SD, Rao, KV and Mihailovich, N (1979). Neoplastic response of mouse tissues during perinatal age periods and its significance in chemical carcinogenesis. Natl Cancer Inst Monogr 51: 239-250
47. Sorrentino, B (2010). Assessing the risk of T-cell malignancies in mouse models of SCID-X1. Mol Ther 18: 868-870
48. Barash, H, R Gross, E, Edrei, Y, Ella, E, Israel, A, Cohen, I et al. (2010). Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci USA 107: 2207-2212
49. Ciuffi, A and Barr, SD (2011). Identification of HIV integration sites in infected host genomic DNA. Methods 53: 39-46
50. Bibbiani, C, Tongiani, R and Viola-Magni, MP (1969). I. Quantitative determination of the amount of DNA per nucleus by interference microscopy. J Cell Biol 42: 444-451